A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

To join this study, women need to have breast cancer that is oestrogen receptor-positive (ER+) and HER2-negative, which has either spread locally or to other parts of the body. You would also need to have received previous treatment for your advanced breast cancer. On top of that, your general health would need to be good enough to take part, meaning your body is working fairly well, and you can generally carry out your day-to-day activities.

There are also some reasons why you wouldn't be able to join. For example, if you currently have a serious infection that isn't under control, or if you've had major surgery or other specific cancer treatments very recently (within the last 4 weeks). People who can't take medicines by mouth, or have serious heart problems, or have active issues with alcohol or drug misuse would also not be able to participate. The study is for women aged 18 or older.

If you join this study, it would involve regular visits to the clinic for check-ups and assessments. You would be given the study drugs, H3B-6545 and palbociclib, which are taken by mouth (as tablets or capsules). The dose of these drugs would be carefully monitored. You would need to have blood tests regularly, and doctors would check your general health, including how your organs are working. They would also ask about any side effects you might be experiencing. The exact number of visits and the total length of time you'd be involved can vary, but studies like this typically involve frequent checks initially, followed by less frequent visits if the treatment is stable. You would remain in the study as long as the treatment is helping you and you are tolerating it well.